NCODA Logo

Luspatercept EMR Assessment Tool

The newest first-line approval of Reblozyl® (luspatercept) in the treatment landscape of myelodysplastic syndrome (MDS) patients allows quicker access to this effective therapy. The approval, based on interim results from the Phase 3 COMMANDS trial, grants first-line treatment for anemia in adult patients with low to intermediate risk MDS without previous erythropoiesis stimulating agent (ESA) use who may require regular red blood cell transfusions.

To aid in identifying patients who meet eligibility requirements for luspatercept (Reblozyl®) therapy, NCODA has created helpful workflow tools that include step-by-step instructions for EPIC and OncoEMR users. For OncoEMR users, these tools will also help in tasking, group inboxing and creating reports for future use.

Please select the Electronic Medical Record (EMR) system for instructions.